G. Alves

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

J. Bono, C. Sternberg, M. Borre, 2021, The Lancet.

GASTROINTESTINAL STROMAL TUMOR: OUTCOMES OF THE PAST DECADE IN A REFERENCE INSTITUTION IN SOUTHERN BRAZIL

G. V. Alves, E. Everling, T. J. Grezzana-Filho, 2022, Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery.

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

M. Lowery, L. Wyrwicz, F. Rivera, 2023, Annals of Oncology.

DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.

G. Schwartsmann, M. Franzoi, M. V. Antunes, 2018, Clinical biochemistry.

Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts.

G. de Castro, P. Mora, U. Nicolau, 2018, Critical reviews in oncology/hematology.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Joon-Oh Park, H. Harputluoglu, G. Brandi, 2023, The Lancet.

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

V. Grégoire, J. Machiels, K. Harrington, 2020, Future oncology.

Hyperparathyroidism secondary to hypovitaminosis D in hypoalbuminemic is less intense than in normoalbuminemic patients

T. Furlanetto, M. Premaor, G. V. Alves, 2004, Endocrine.

Prognosis of Thyroid Cancer Related to Pregnancy: A Systematic Review

T. Furlanetto, G. V. Alves, A. P. Santin, 2011, Journal of thyroid research.

LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

J. Machiels, D. Rischin, R. Swaby, 2022, Annals of Oncology.

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.

M. Lowery, Z. Wainberg, L. Wyrwicz, 2023, The Lancet. Oncology.